Hydroxychloroquine Dose and Hospitalization Risk in People with Systemic Lupus Erythematosus

A new  study found a connection between lower doses of hydroxychloroquine (HCQ) and increased risk of hospitalization in people with active systemic lupus erythematosus (SLE). HCQ (known commercially as Plaquenil®) is safe and widely used for more favorable outcomes in people with active disease.

Researchers reviewed the records of 2,974 people with SLE who use HCQ. People taking lower weight-based and non-weight-based doses of the therapy were associated with increased hospitalizations for active disease compared to those with a higher prescribed dosing. 

HCQ treatment reduces disease activity, damage, and mortality for people with lupus. However, eye damage is associated with long-term use of the drug. Consult your physician before making any changes to your medication. 

This study was co-authored by Karen Costenbader, MD, MPH, Medical Scientific Advisory Council Chair for the Lupus Foundation of America. Learn more about hydroxychloroquine.

Read the study